Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
280 trials
Recruiting nowPhase 3
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Recruiting nowPhase 2
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Recruiting nowPhase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Recruiting nowPhase 2
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Recruiting nowPhase 3
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Recruiting nowPhase 2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Recruiting nowPhase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Recruiting nowPhase 2
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Recruiting nowPhase 2
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Recruiting nowPhase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Recruiting nowPhase 2
Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer
Recruiting nowPhase 2
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Recruiting nowPhase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Recruiting nowPhase 2
A Study of YL202 in Patients With Advanced Solid Tumors
Recruiting nowPhase 3
FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial